Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors

NCT03950609 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03950609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03950609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 30, 2019
Completion date
March 30, 2028
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced carcinoid tumor, digestive system neuroendocrine neoplasm, multiple endocrine neoplasia type 1, neuroendocrine neoplasm, unresectable carcinoid tumor